Edition:
United States

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

15.82USD
25 May 2017
Change (% chg)

-- (--)
Prev Close
$15.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
67,511
52-wk High
$24.00
52-wk Low
$8.71

Latest Key Developments (Source: Significant Developments)

Versartis Q1 loss per share $0.85
Thursday, 27 Apr 2017 04:05pm EDT 

April 27 (Reuters) - Versartis Inc ::Versartis reports first quarter 2017 financial results.Q1 loss per share $0.85.Versartis Inc - research and development (research and development) expenses for quarter ended march 31, 2017 were $22.0 million, compared to $18.2 million.Q1 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.  Full Article

Versartis reports new data on Somavaratan in growth hormone deficiency
Monday, 3 Apr 2017 07:30am EDT 

Versartis Inc : Versartis reports new data on long-acting Somavaratan in growth hormone deficiency at endo 2017 . Baseline characteristics of phase 3 velocity trial population balanced between study arms and comparable to phase 2 .Further results from vital trial in adult ghd-similar Somavaratan PK/PD data in U.S., Japanese children support using same dose in ongoing phase 3 trials.  Full Article

Versartis Q4 loss per share $0.64
Tuesday, 21 Feb 2017 04:05pm EST 

Versartis Inc : Versartis reports fourth quarter 2016 financial results . Q4 loss per share $0.64 .Q4 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

Advent Life Sciences reports a 6.6 pct passive stake in Versartis-SEC filing
Friday, 10 Feb 2017 06:10am EST 

Versartis Inc :Advent Life Sciences Llp reports a 6.6 percent passive stake in Versartis Inc as of December 31, 2016 -sec filing.  Full Article

Versartis reports Q3 loss per share of $0.92
Thursday, 3 Nov 2016 08:31pm EDT 

Versartis Inc : Versartis reports third quarter 2016 financial results . Q3 loss per share $0.92 .Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Versartis reports Q3 loss per share of $0.92
Thursday, 3 Nov 2016 04:05pm EDT 

Versartis Inc : Versartis reports third quarter 2016 financial results . Q3 loss per share $0.92 .Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Versartis announces pricing of follow-on offering
Wednesday, 28 Sep 2016 09:02am EDT 

Versartis Inc : Announces pricing of follow-on offering .Pricing of an underwritten public offering of 4.9 million shares of its common stock at a public offering price of $12.25 per share.  Full Article

Versartis reports proposed offering of common stock
Tuesday, 27 Sep 2016 04:01pm EDT 

Versartis Inc :Versartis announces proposed offering of common stock.  Full Article

Versartis presents data for Somavaratan
Friday, 2 Sep 2016 04:05pm EDT 

Versartis Inc : Versartis presents efficacy, safety, metabolic and adherence data for somavaratan in oral session at international congress of endocrinology . Somavaratan is currently being evaluated for treatment of pediatric ghd in pivotal phase 3 velocity trial in u.s., canada and europe . Data for pivotal phase 3 velocity trial anticipated in q3 2017, and j14vr5 phase 2/3 trial in japan .In adult ghd, top-line results from phase 2 vital trial in u.s., europe and australia are expected during second half of 2016..  Full Article

Versartis completes enrollment in phase 3 Velocity trial of Somavaratan in Pediatric GHD
Monday, 22 Aug 2016 08:30am EDT 

Versartis Inc :Announces completion of enrollment in phase 3 Velocity trial of Somavaratan in Pediatric GHD; line results are anticipated in q3 2017..  Full Article

More From Around the Web

BRIEF-Versartis announces three year Somavaratan data

* Three-year Vertical/Vista study results support selection of 3.5 mg/kg twice-monthly dose regimen for phase 3 Velocity trial underway Source text for Eikon: Further company coverage: